Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 2 institutions in 2 countries.
Michely Laiany Vieira MouraLaboratory of Toxicological Genetics-LAPGENIC, Graduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina 64049-550, Brazil.
Ag-Anne Pereira Melo de MenezesLaboratory of Toxicological Genetics-LAPGENIC, Graduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina 64049-550, Brazil.
José Williams Gomes de Oliveira FilhoLaboratory of Toxicological Genetics-LAPGENIC, Graduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina 64049-550, Brazil.ORCID 0000-0001-6492-0111
Maria Luiza Lima Barreto do NascimentoLaboratory of Toxicological Genetics-LAPGENIC, Graduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina 64049-550, Brazil.
Antonielly Campinho Dos ReisLaboratory of Toxicological Genetics-LAPGENIC, Graduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina 64049-550, Brazil.
Alessandra Braga RibeiroCBQF-Centro de Biotecnologia e Química Fina-Laboratório Associado, Escola Superior de Biotecnologia, Universidade Católica Portuguesa, Rua Diogo Botelho 1327, 4169-005 Porto, Portugal.
Felipe Cavalcanti Carneiro da SilvaLaboratory of Toxicological Genetics-LAPGENIC, Graduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina 64049-550, Brazil.ORCID 0000-0002-4241-3036
Adriana Maria Viana NunesDepartment of Biophysics and Physiology, Federal University of Piauí, Teresina 64049-550, Brazil.
Hercília Maria Lins RolimLaboratory of Pharmaceutical Nanosystems-NANOSFAR, Graduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina 64049-550, Brazil.ORCID 0000-0003-4469-6858
Ana Amélia de Carvalho Melo CavalcanteLaboratory of Toxicological Genetics-LAPGENIC, Graduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina 64049-550, Brazil.
João Marcelo de Castro E SousaLaboratory of Toxicological Genetics-LAPGENIC, Graduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina 64049-550, Brazil.ORCID 0000-0002-5085-1482
Universidade Federal do Piauí · BRUniversidade Católica Portuguesa · PT
Funding
National Council for Scientific and Technological Development Ed. 427366/2018-6 CNPq
6 · The paper itself
Abstract
The study aimed to evaluate the antitumor and toxicogenetic effects of liposomal nanoformulations containing citrinin in animal breast carcinoma induced by 7,12-dimethylbenzanthracene (DMBA).
Indexed as
breast cancercytotoxicityfungal metabolitesnanotechnology
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Advances in Antitumor Effects Using Liposomal Citrinin in Induced Breast Cancer Model. · full record | OpenQuestion